
News|Articles|February 13, 2019
Gamifant for Primary Hemophagocytic Lymphohistiocytosis
Author(s)Drew Boxler
Advertisement
Gamifant (emapalumab-lzsg, Sobi)
Indications: patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
Dosage: 1 mg/kg as an intravenous infusion over 1 hour twice per week; Administer dexamethasone concomitantly with GAMIFANT.
Contraindications:None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
5







































